SCHEMBL16990484

SCHEMBL16990484

CC[C@H](C)[C@H](NC(=O)CC(O)C(Cc1ccccc1)NC(=O)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)CC(C)C)C(C)C)C(=O)N[C@H](C(=O)O)C(C)C

nearest known ligand 0.87

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CTSD P07339 20/20 0.87
REN P00797 1/20 0.87

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16990489 1.00 CTSD (0.87) CTSDREN
SCHEMBL20495546 1.00 CTSD (0.87) CTSDREN
SCHEMBL16990486 1.00 CTSD (0.87) CTSDREN
SCHEMBL16990574 1.00 CTSD (0.87) CTSDREN
SCHEMBL15606240 1.00 CTSD (0.87) CTSDREN
SCHEMBL18745905 1.00 CTSD (0.87) CTSDREN
SCHEMBL16990507 0.95 CTSD (0.79) CTSDREN
SCHEMBL16990512 0.95 CTSD (0.79) CTSDREN
SCHEMBL16997411 0.95 CTSD (0.79) CTSDREN
SCHEMBL18661814 0.95 CTSD (0.79) CTSDREN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10077288-B2 Hydroxystatin derivatives for the treatment of arthrosis MERCK PATENT GMBH (DE) 2018-09-18 US claimed
EP-2877485-B1 HYDROXYSTATIN DERIVATIVES FOR TREATMENT OF ARTHROSIS MERCK PATENT GMBH (DE) 2018-03-14 EP claimed
US-9624264-B2 Hydroxystatin derivatives for the treatment of arthrosis MERCK PATENT GMBH (DE) 2017-04-18 US claimed
US-20170081361-A1 HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS MERCK PATENT GMBH (DE) 2017-03-23 US claimed
US-20150225451-A1 HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS MERCK PATENT GMBH (DE) 2015-08-13 US claimed
US-10077288-B2 Hydroxystatin derivatives for the treatment of arthrosis MERCK PATENT GMBH (DE) 2018-09-18 US disclosed
US-9624264-B2 Hydroxystatin derivatives for the treatment of arthrosis MERCK PATENT GMBH (DE) 2017-04-18 US disclosed
US-20170081361-A1 HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS MERCK PATENT GMBH (DE) 2017-03-23 US disclosed
US-20150225451-A1 HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081361-A1 HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS CTSD, CTSB, CTSZ CTSD 1/4885REN 779/4885
US-10077288-B2 Hydroxystatin derivatives for the treatment of arthrosis CTSD, CTSB, CTSZ CTSD 1/4885REN 779/4885
US-20150225451-A1 HYDROXYSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS CTSD, CTSB, CTSZ CTSD 1/4885REN 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.